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Abstract
Background: Several anti-viral drugs have demonstrated efficacy in preventing Cytomegalovirus (CMV) infections in solid
organ transplant (SOT) patients. The recently approved valganciclovir is the most commonly used and most expensive drug
for CMV prevention. The safety and efficacy data have been drawn from a single trial. We hypothesized that valganciclovir
may not be as safe as nor more effective than other therapies for CMV prevention.
Methods: All experimental and analytical studies that compared valganciclovir with other therapies for prevention of CMV
infection after SOT were selected. Based on meta-analytic and multivariate regression methodologies we critically analyzed
all available evidence.
Findings: Nine studies were included (N=1,831). In trials comparing valganciclovir with ganciclovir, the risk for CMV disease
is 0.98 (95% Confidence Interval (95%CI) 0.67 to 1.43; P=0.92; I
2=0%). Valganciclovir was significantly associated with the
risk of absolute neutropenia (,1,500/mm
3) compared with all therapies (Odds Ratio (OR) 3.63 95%CI 1.75 to 7.53; P=0.001;
I
2=0%); with ganciclovir only (OR 2.88, 95%CI 1.27 to 6.53; P=0.01; I
2=0%); or with non-ganciclovir therapies (OR 8.30,
95%CI 1.51 to 45.58; P=0.01; I
2=10%). For a neutropenia cut-off of ,1,000/mm
3, the risk remained elevated (OR 1.97,
95%CI 1.03 to 3.67; P=0.04; I
2=0%). For every 24 patients who receive valganciclovir prophylaxis, one more will develop
neutropenia compared to other therapies. The risk of late-onset CMV disease with valganciclovir was similar to ganciclovir
and higher than those with non-ganciclovir therapies (OR 8.95, 95%CI 1.07 to 74.83; P=0.04; I
2=0%]. One more patient will
develop late-onset CMV disease for every 25 who receive valganciclovir compared to treatment with non-ganciclovir
therapies. The risk of CMV tissue-invasive disease in liver recipients receiving valganciclovir was 4.5 times the risk seen with
ganciclovir [95%CI 1.00 to 20.14] (p=0.04). All results remained consistent across different study designs, valganciclovir
doses, and CMV serostatus.
Conclusions: Valganciclovir shows no superior efficacy and significantly higher risk of absolute neutropenia, CMV late-onset
disease, and CMV tissue-invasive disease compared to other standard therapies. Due to the availability of efficacious, safer,
and lower cost drugs (high-dose acyclovir, valacyclovir, ganciclovir), our results do not favor the use of valganciclovir as a
first-line agent for CMV preemptive or universal prophylaxis in SOT patients.
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Introduction
Cytomegalovirus (CMV) is the most frequent opportunistic
infection in solid organ transplant (SOT) patients, causing either
CMV syndrome (fever, malaise and cytopenia) or CMV disease
usually in the first year post-transplant [1,2]. Several approaches
have evolved to prevent this infection, including universal
prophylaxis with anti-viral agents (i.e. acyclovir, valacyclovir,
ganciclovir, valganciclovir), and pre-emptive strategy with ganci-
clovir or valganciclovir. Efficacy superiority has not been
demonstrated for either a specific strategy or anti-viral drug in
numerous clinical trials and meta-analyses [2–4]. Nonetheless,
valganciclovir is the most widely employed drug for pre-emptive
and universal prophylaxis, used in approximately two-thirds of all
SOT patients [5,6]. The reasons for this popularity are
multifactorial, including the convenience of once daily dosing,
limitations on the production of oral ganciclovir, and influential
marketing strategies by the manufacturer. Despite its commercial
success, we hypothesize that valganciclovir may be less safe and
not more effective than its substantially less expensive alternatives,
oral ganciclovir, oral acyclovir or valacyclovir for the prevention of
CMV.
Valganciclovir (L-valyl ester prodrug of ganciclovir with higher
bioavailability than oral ganciclovir) received FDA approval in
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risk (defined as CMV seronegative recipients of organs from CMV
seropositive donors) kidney, kidney-pancreas and heart transplant
recipients based on a non-inferiority trial comparing this drug with
oral ganciclovir. The trial by Paya et al [7] showed that
valganciclovir was not inferior to ganciclovir for transplant
recipients at high risk for cytomegalovirus. A notable exception
was observed in liver recipients in whom a significantly higher rate
of CMV invasive-tissue disease occurred in those receiving
valganciclovir compared with the ganciclovir recipients; accord-
ingly, the FDA did not approve valganciclovir for prophylaxis
following liver transplantation [8]. Furthermore, the same trial
suggested that neutropenia may be an important adverse effect of
valganciclovir prophylaxis, affecting 8% of those taking the drug
[7].
Since the original trial [7] was published, many subsequent
clinical studies using valganciclovir for either pre-emptive or
universal prophylaxis in solid organ transplant recipients have
been published [9–24]. Recognizing that the single, non-inferiority
original trial [7] cannot address all clinically relevant issues, we
undertook a meta-analysis of all available data from both this
pivotal trial and from more recently published studies to extend
our knowledge about the safety and efficacy of valganciclovir
prophylaxis in the setting of solid organ transplantation.
The efficacy aim of our study is to determine the reduction in
CMV disease and the safety aim is to determine the risks of
neutropenia, opportunistic infections, late-onset CMV disease, and
death among patients receiving valganciclovir versus other
preventive therapies (i.e. ganciclovir, valacyclovir, and high-dose
acyclovir), or approaches (i.e. prophylaxis and preemptive).
Materials and Methods
Literature Search
A systematic literature search was performed without language
restrictions from inception to May 2008 in the following databases:
Medline, Embase, and Cochrane Library. In addition, we
searched abstracts published in the same time period from the
following meetings: Infectious Diseases Society of America,
American Transplantation Congress, and the Interscience Con-
ference on Antimicrobial Agents and Chemotherapy. Relevant
internet sites such as the Food and Drug Administration reports
[8] and trial results repositories (www.clinicalstudyresults.org and
www.clinicaltrialresults.org) were also searched. The keywords
used were valganciclovir, valcyte, cytomegalovirus, prevention,
prophylaxis, preemptive, organ, lung, pulmonary, kidney, renal,
liver, hepatic, heart, cardiac, pancreas, transplant, and transplan-
tation.
Study Selection
Inclusion Criteria: All experimental (randomized), and analyt-
ical (cohort and case-control) studies which primarily aimed to
compare valganciclovir with other therapies or approaches for
prevention of CMV disease after SOT were selected for both
safety and efficacy analyses.
Exclusion Criteria: Non-comparative observational studies were
not included in the meta-analysis, but were discussed as descriptive
data.
Data Extraction
A standardized form was used to abstract and collect the
following variables: authors; publication year; study design; type of
allograft; gender; mean age; sample size; CMV serostatus;
induction therapy; maintenance immunosuppressive therapy;
valganciclovir regimen; comparator regimen; length of CMV
prophylaxis; length of follow up; white blood cell count; neutrophil
count; CMV viremia; CMV syndrome; CMV disease; opportu-
nistic infections; and survival. Any disagreement was resolved by
further review of the study and consensus among two authors
(A.C.K and A.G.F).
Safety and Efficacy Definitions
Neutropenia: Absolute neutrophil count (ANC) less than 1,000
to 1,500 cells/mm
3, which is considered grade 2 toxicity on the
National Cancer Institute toxicity criteria [25].
CMV Disease: The presence of CMV syndrome (viral detection
with fever, malaise, or cytopenia) and/or end-organ disease
involvement by cytomegalovirus [26].
CMV Tissue-Invasive Disease: The presence of end-organ
disease involvement by cytomegalovirus [26].
Late-Onset CMV Disease: The occurrence of CMV disease
after the completion of universal prophylaxis.
Deaths: All-cause mortality.
Statistical Analysis
The data was pooled by using the Mantel-Haenszel fixed-effects
model [27] and the DerSimonian and Laird [28] random-effects
model. The Q statistic method was used to assess statistical
heterogeneity and the I-squared method to assess the magnitude of
variation secondary to heterogeneity [29]. All results were
reported with the fixed-effects model, except when significant
heterogeneity (p,0.1 or I
2.50%) was detected. For studies with
no event of interest in a treatment group, 1.0 was added to all cells.
The software used was Comprehensive Meta-Analysis version 2.0
(Biostat, Englewood, New Jersey). We performed multivariate
logistic regression analyses using the data from the FDA [8] and
from the published data from this trial [7,30], on overall CMV
disease and tissue invasive CMV at 6 and 12 months. The analysis
evaluated only liver and kidney transplants, since these were
groups with the largest sample sizes, thus resulting in the most
stable parameter estimates. Censoring due to death could not be
performed because we did not have patient-level mortality
information on when or for which groups deaths occurred before
6 months. In accordance with the Consolidated Standards of
Reporting Trials guidelines [31], we relied on interactions between
treatment and subgroups with the aim to avoid misinterpretation
and to better understand the trial results for subgroups of patients.
Because of the known conservative nature of this test, an
interaction test with a p value less than 0.1 is considered
statistically significant. The software used was SAS version 9.1.3
(SAS Institute, Cary, North Carolina). The number needed to
treat and the number needed to harm were based on the odds
ratios and control arm events rate of the included trials [32]. Since
the event rates are low across the treatment groups and subset
analyses, the odds ratio (OR) is used to estimate the relative risk
(RR) and the treatment group effect is described in terms of risk
instead of odds. The Jadad score was used to evaluate the quality
of randomized studies (table 1), the QUOROM criteria for the
search methodology (Figure 1), and the MOOSE checklist (Table
S1) was completed to evaluate the quality of our study report. The
cohort and case-control studies were not scored because there are
no validated scoring systems for these study designs. Funnel plot,
Egger regression and the Begg and Mazumdar methods were used
to evaluate publication bias [32–34]. Statistical power calculations
were performed based on the comparison of two independent
proportions using the software PASS version 2005 (Number
Crunching Statistical Systems, Kaysville, Utah).
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Nine studies met the prospectively defined inclusion criteria:
three randomized [7,9,10]; three cohort [11–13]; and three case-
control [14–16] studies. All other studies either met the exclusion
criteria defined by the absence of a comparator arm (8 studies), or
did not meet the inclusion criteria defined by the absence of a
valganciclovir arm (44 studies). A total of 1,831 patients were
included in our analysis. The characteristics of each study are
presented in table 1. Based on their different study designs, we
performed several sensitivity analyses and concluded that they can
be appropriately combined by the meta-analytic methodology.
These analyses are all described below (pages 10 and 13).
Efficacy Analysis
A. Prevention of CMV Disease in All Trials. The efficacy
meta-analysis consisted of seven trials comparing valganciclovir
against ganciclovir (N=1,410) [7,10,11,13–16]: two randomized
[7,10]; two cohort [11,13]; and three case-control studies [14–16].
Two of the nine identified trials were excluded because
comparators other than universal ganciclovir were used in one
trial each: one with medium-dose acyclovir [12] and the other with
pre-emptive approach [9].
The overall risk for CMV disease does not differ significantly
between the valganciclovir and ganciclovir groups [OR 0.98
(95%CI 0.67 to 1.43; P=0.92; I
2=0%)] (Fig. 2). The analysis
based on the study design shows: All prospective trials [OR 1.11
(95%CI 0.69 to 1.77; P=0.67; I
2=8%)]; only randomized trials
[OR 1.31 (95%CI 0.50 to 3.40; P=0.58; I
2=54%)]. The analysis
by the specific valganciclovir dose shows: valganciclovir 900 mg
[OR 1.11 (95%CI 0.69 to 1.77; P=0.67; I
2=8%)]; valganciclovir
450 mg [OR 0.76 (95%CI 0.40 to 1.44; P=0.40; I
2=0%)]. The
analysis based on allograft type was possible only for kidney/
kidney-pancreas recipients [OR 0.99 (0.55 to 1.76); P=0.97;
I
2=26%].
Sensitivity Analysis
The Weng et al study [13] included patients who did not have
documented viral replication but were clinically treated as CMV
disease (which could have caused significant confounding results),
and the Said et al [10] study gave a regular (90-day) and a shorter
(14-day) prophylaxis duration (which could decrease comparability
with other studies). These two studies were included/excluded
from every efficacy analysis as part of our sensitivity analysis. The
overall results with/without these studies (including the 14-day and
90-day arms of Said et al analyzed separately) remained similar.
We understand that evaluating a 90-day course against a 14-day
course has poor scientific comparability since it is well-known that
these regimens may produce different effects. However, since the
efficacy results remain similar with both regimens, we kept the 14-
day course comparison used for both experimental and control
arms. The low-dose valganciclovir (450 mg) efficacy analysis
showed an OR 1.08 (95%CI 0.45 to 2.60; P=0.87; I
2=0%).
In the aim to understand if the overall sample size analyzed for
efficacy (Total N=1,410) would be large enough to detect a
potential significant valganciclovir advantage, we calculated the
power needed to detect valganciclovir superiority based on a 7%
reduction of CMV disease (12% to 5%), as suggested in the
original trial by Paya et al. [7]. We found that a total N=624
would provide a 90% power with a two-tailed alpha of 0.05 to
detect a 7% decrease in CMV disease with valganciclovir. Thus,
our efficacy meta-analysis sample size (N=1,410) was adequately
powered to detect valganciclovir superiority.
B. Prevention of CMV Disease in the D+/R2 Subgroup
Only. The D+/R2 group was separately analyzed for efficacy.
The overall efficacy remains similar between valganciclovir and
ganciclovir: OR=0.87 (95%CI 0.52 to 1.45; P=0.59; I
2=0%). If
just the prospective studies are included, the OR is 0.93 (95%CI
0.54 to 1.58; P=0.78; I
2=0%).
Safety Analysis
A. Risk of Neutropenia. Six studies evaluated the
occurrence of neutropenia (ANC,1,500/mm3) during
prophylaxis (N=996) [7,9,11,12,14,16]. One study was excluded
because it evaluated only leucopenia [15].
We found that valganciclovir significantly increases the risk of
neutropenia by 263% (OR 3.63, 95%CI 1.75 to 7.53; P=0.001;
I
2=0%) compared to all other preventive therapies (Fig. 3A). The
cumulative safety meta-analysis by publication year (Fig. 3B)
demonstrates that a statistically significant neutropenia with
valganciclovir has consistently been observed since the year of
2004. When the studies which compared valganciclovir and
ganciclovir only are analyzed, the use of valganciclovir is
significantly associated with the risk of neutropenia by 188%
(OR 2.88, 95%CI 1.27 to 6.53; P=0.01; I
2=0%). When the
Figure 1. Quorom Trial Flow.
doi:10.1371/journal.pone.0005512.g001
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(acyclovir or preemptive) [9,12] are analyzed, the use of
valganciclovir is significantly associated with the risk of neutrope-
nia by 730% (OR 8.30, 95%CI 1.51 to 45.58; P=0.01; I
2=10%).
The analyses for risk of neutropenia based on the study design
shows: All prospective studies [OR 2.87 95%CI 1.15 to 7.14;
P=0.002; I
2=0%]; only prospective studies which used ganci-
clovir as a comparator [OR 2.83 95%CI 1.05 to 7.62; P=0.04;
I
2=0%]; only randomized studies [OR 2.82 95%CI 1.05 to 7.60;
P=0.04; I
2=0%]). If an ANC cut-off of 1,000 cells/mm
3 is used,
the risk of neutropenia remains significantly elevated (OR 1.97,
95%CI 1.03 to 3.67; P=0.04; I
2=0%).
Sensitivity Analysis
Induction therapy with anti-thymocyte preparations and the use
of mycophenolate mofetil (MMF) are known potential causes of
neutropenia. Two trials did not use MMF [12,15] but just one
reported neutropenia [12], which also showed elevated risk [OR
21.6 95%CI 1.20 to 388.6; P=0.037]. Valganciclovir is associated
with increased risk of neutropenia despite the absence of induction
therapy [OR 5.11 95%CI 1.32 to 19.74; P=0.018; I
2=49%].
Neutropenia may be related to the degree of drug exposure. We
performed an analysis according to the valganciclovir dose. The
results for the valganciclovir 900 mg/day compared to ganciclovir
demonstrate a statistically significantly increased risk of neutrope-
nia (OR 2.87 95%CI 1.15 to 7.14; P=0.02; I
2=0%), and the
results from the valganciclovir 450 mg/day show similarly
increased risk, but it was not significantly different from
ganciclovir (OR 3.01 95%CI 0.71 to 12.80; P=0.14; I
2=0%).
For every 24 patients who receive valganciclovir for CMV
prophylaxis, one more patient will develop significant neutropenia
compared to control treatment strategies across all studies
considered (i.e. number needed to harm).
B. Opportunistic Bacterial and Fungal Infections. Data
were not available for this analysis.
C. Survival. Survival could be abstracted from 6 trials
[7,9,11,12,14,16]. The analysis shows that valganciclovir was not
significantly associated with poorer survival (OR 1.29 [95%CI
0.70 to 2.38]; P=0.40; I
2=0%).
D. Risk of Late-Onset CMV Disease in All Trials. Late-
onset CMV disease is defined as the occurrence of CMV disease
after the completion of universal prophylaxis. The overall risk for
late-onset CMV disease with valganciclovir compared to ganciclovir
is 1.05 (95%CI 0.67 to 1.64; P=0.84; I
2=0%). The absence of
difference in late-onset CMV-disease is likely secondary to the fact
that universal ganciclovir is also associated with late-onset CMV
disease [7,35–37]. We also analyzed separately the two trials which
did not use ganciclovir prophylaxis as control. The results show a
statistically significant 795% higher rate of late-onset CMV disease
with valganciclovir compared to control (acyclovir or preemptive
therapy) [OR 8.95 (95%CI 1.07 to 74.83; P=0.04; I
2=0%).
One more patient will develop late-onset CMV disease for every
25 recipients who receive valganciclovir for CMV universal
prophylaxis, compared to controls with no oral ganciclovir
therapies.
E. Risk of Late-Onset CMV Disease in the D+/R2
Subgroup Only. Data were not available for this analysis.
F. Risk of CMV Disease in Liver Recipients in the Pivotal
Trial. The FDA subset analyses [8] showed that the rate of
CMV disease was higher in the liver recipients who received
valganciclovir (19% [22/118]) than among those who received
ganciclovir (12% [7/59]) for prophylaxis. Also, the rates of CMV
tissue-invasive disease for liver recipients in the valganciclovir and
in the ganciclovir arms were respectively 14% (16/118) and 3%
(2/59). Thus, the FDA did not approve valganciclovir for liver
recipients. Our multivariate logistic regression analyses based on
the above data shows the following: At 6 months, we found that
there are statistically significant organ by treatment interactions for
both overall CMV disease (p=0.008) and tissue-invasive CMV
(p=0.009). Specifically, for the liver recipient subgroup, the 6-
month risk of having CMV tissue-invasive disease for the
valganciclovir (14%) group is 4.5 times [95%CI 1.00 to 20.14]
(p=0.04) the risk in the ganciclovir group (3%). At 12 months,
there are also significant organ by treatment interactions for both
overall CMV disease (p=0.07) and tissue-invasive CMV
(p=0.05). The 12-month risk of a liver recipient having tissue-
invasive CMV disease for the valganciclovir group (14%) is 3.2
times [95%CI 0.99 to 11.19] (p=0.05) the risk in the ganciclovir
group (5%). The tissue-invasive CMV results indicate a qualitative
interaction because the significant result in the liver recipient
group was in the opposite direction of the results for other allograft
groups.
Figure 2. Efficacy: Reduction in CMV Disease.
doi:10.1371/journal.pone.0005512.g002
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Trials. We identified two other published studies which used
valganciclovir in liver recipients [16,38], but were not included in
the meta-analysis because both were non-comparative
observational studies. Both were retrospective and evaluated
universal prophylaxis with valganciclovir. The first [38]
described an overall rate of CMV disease (N=203) of 17%, but
the rate in the CMV D+/R2 group (N=59) was 26% with
valganciclovir prophylaxis. The second study [16] found an overall
(N=60) rate and CMV D+/R2 group (N=15) rate of 3% and
7%, respectively. Both studies had similar baseline proportion of
high-risk patients with CMV D+/R2 status [22% [16] and 26%
[38]], similar immunosuppressive regimens (FK;MMF;Prednisone)
and target FK concentrations, no use of induction, and follow up
for 12 or more months. The lack of prospective controls in both
studies may account for the differences in the rates of CMV
disease. We calculated an exact 95% CI for the CMV disease rates
in the high-risk (CMV D+/R2) groups of both trials to compare
them with the results from the original trial [7]. We found a rate of
7% (95%CI 0.2% to 32%) for Park et al [16], and 26% (95%CI
15% to 40%) for Jain et al [38]. Both confidence intervals include
the estimated CMV disease rate (20%) and CMV tissue-invasive
disease (14%) found in the liver recipients from the pivotal trial [7].
Furthermore, there is no significant difference in the CMV disease
rates among all three studies (p=0.2, Chi-square test).
H. Publication Bias. No publication bias was detected by
Egger regression (intercept=0.264; standard Error=0.777;
P=0.748), or Begg and Mazumdar rank correlation (Kendall’s
Figure 3. A: Safety: Risk of Absolute Neutropenia. B: Cumulative Safety: Risk of Absolute Neutropenia.
doi:10.1371/journal.pone.0005512.g003
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(figure 4), and despite the small number of studies, no substantial
asymmetry was observed.
Discussion
Our comprehensive evidence-based analysis of published studies
exploring CMV prophylactic strategies in SOT patients failed to
demonstrate greater efficacy of valganciclovir over standard
ganciclovir. We found that universal prophylaxis with valganci-
clovir is significantly more toxic than with oral ganciclovir (188%
higher rate of neutropenia), or non-ganciclovir therapies (730%
higher rate of neutropenia), in which both have demonstrated
efficacy for CMV prophylaxis [2,4,39,40].
The higher rate of neutropenia observed with valganciclovir is
independent of the study design, type of control, or concomitant
use of regimes such as T-cell depleting induction therapies or
MMF which might also suppress the bone marrow. In addition,
the remarkable consistency of the risk estimates for neutropenia
seen in our cumulative meta-analysis (Fig. 3B) demonstrates that
the risk of neutropenia has been statistically significantly higher
with valganciclovir compared to other therapies since 2004. In
view of these findings, the question remains as to why
valganciclovir is so widely employed by clinicians and surgeons
[5,6] if it is no more effective and less safe than other less costly
alternatives?
Despite its low bioavailability, ganciclovir (3 g/day) was found
to be an effective suppressant of CMV reactivation and clinical
disease in SOT patients who took it for 3 months prophylactically
after transplant [2,4,35,41,42]. Valganciclovir is the L-valyl ester
prodrug of ganciclovir that has greater oral bioavailability and
yields plasma levels of ganciclovir that are comparable to, or even
higher than, intravenous administration of 5 mg/kg ganciclovir
[43,44]. Although both drugs preferentially inhibit viral DNA
polymerases, they also interact with host enzymes, resulting in
varying degrees of marrow suppression. It stands to reason,
therefore, that the more highly available valganciclovir would tend
to have greater marrow toxicity as a consequence of its higher and
more prolonged plasma concentrations of the parent drug,
ganciclovir. Indeed, the pivotal study [7] comparing the two
agents revealed 8.2% and 3.2% incidences of neutropenia, for
valganciclovir and ganciclovir, respectively. Although one might
expect greater efficacy to accompany the higher plasma levels of
ganciclovir that are seen with oral valganciclovir, this has not
proved to be the case by our comprehensive analysis. This intuitive
clinical reasoning commonly used for the treatment approach may
not be applicable for the prophylactic approach, in which higher
drug concentrations may not translate into further benefits, but
rather more side effects.
The rates of neutropenia that we found most likely represent an
underestimation of this important clinical problem, due to the
variability and imprecision in reporting the degree of neutropenia
in the various studies. ANC,1,000 and 1,500 mm
3 were
considered representative of neutropenia in most studies, but the
depth of neutropenia was not specifically or systematically
reported. Thus, it is not known what proportion of patients had
more severe levels of neutropenia, of which could impart a
substantially greater infection risk to the patient. Surrogate end-
points for safety commonly used in prophylaxis studies (i.e.
‘stopping valganciclovir’, ‘requiring growth factor’) are influenced
Figure 4. Funnel plot: Evaluation of Publication Bias.
doi:10.1371/journal.pone.0005512.g004
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and from hospital-to-hospital; may not correlate with the
magnitude of neutropenia or actual risk of developing infections;
and may be potentially misleading about the actual valganciclovir
effect in SOT patients [45,46]. The risk of serious opportunistic
infections secondary to valganciclovir-induced neutropenia could
not be analyzed, given the lack of data, but it is notable that there
was a trend toward increased risk of death in the population who
received valganciclovir. However, a direct cause-effect between
valganciclovir and higher risk of infectious diseases is yet to be
demonstrated in future studies, in which underreporting could be
avoided by the systematic collection of all post-transplant
infectious diseases.
Another potential limitation of our results is related to the lack
of trial reporting on the rate of CMV resistance to ganciclovir in
most studies. However, the randomized prospective study by
Boivin et al [47] demonstrated a very low incidence of CMV
genotypic resistance (1.9%) in multiple transplant centers.
Additionally, the genotypic presence of mutations is not necessarily
associated with clinical resistance. Other limitations that are
intrinsic to the statistical methodology used in our study include: 1)
the use of aggregated data rather than individual data; and 2) the
normality assumption, which may not hold for subgroup analysis.
Of note, the Jadad scores used to evaluate the quality of included
studies have been validated only in randomized trials, so the scores
of the non-randomized studies included in our analyses may not
have the same reliability.
Paya et al [7] reported that valganciclovir was ‘‘as clinically
effective and well-tolerated as oral ganciclovir for CMV
prevention in high risk SOT recipients’’. According to the
CONSORT statement [31,48], ‘‘…equivalence trials aim to
determine whether intervention is therapeutically similar to
another, usually an existing treatment…and non-inferiority trials
seek to determine a new treatment is no worse than a reference
treatment’’. Therefore, based on the fact this trial [7] had a non-
inferiority design, the correct interpretation would be that
valganciclovir is ‘no worse than’ or ‘not inferior to’ ganciclovir.
A non-inferiority margin of 25% or 2D=25.0% (i.e. lower
bound of 95% CI) was used in the valganciclovir trial [7], which
means that valganciclovir could show up to a 5% higher rate
(absolute difference) of CMV disease than ganciclovir and still be
deemed non-inferior to ganciclovir. The results of the intent-to-
treat (ITT) analysis showed a 2D=24.2% (3.1% [95%CI 24.2%
to 11%]) at 6 months; and a 2D=26.8% (1.5% (95%CI 26.8%
to 9.8%]) at 12 months; for the Per Protocol (PP) at 6 months, the
2D=5.1% (3.9% (95%CI 25.1% to 12.9%]). In principle, the
use of the ITT population in a non-inferiority designed trial can
artificially enhance the claim of non-inferiority by diluting the real
treatment differences [49–51], i.e. falsely accepting a new truly
inferior treatment as non-inferior (type I error). Hence, if the
primary outcome of this study was based on the differences in
CMV disease rates in the PP population analysis at 6 months
(2D=25.1%), or on the ITT population analysis at 12 months
(2D=26.8%), valganciclovir would not be considered non-
inferior to ganciclovir.
Based on the original trial [7], valganciclovir appears to be non-
inferior to ganciclovir; however, the fact that both 6-month per
protocol and 12-month intention-to-treat analyses failed to meet
the predefined non-inferiority criteria is troublesome. We
calculated that a sample size of 624 patients would have been
adequate to detect valganciclovir superiority in this trial. It may be
argued that the pivotal trial sample was not large enough to
achieve this end; however, our data, comprising a cohort of 1,410
patients, did not even show a trend for better efficacy based on the
point estimate (OR=0.98) or statistical significance (p=0.91).
Thus, even at sufficient numbers of patients for evaluation, there is
no suggestion of valganciclovir superiority. Our results were not
changed by the analyses of different study designs or D+/R2
serostatus subgroup. The inclusion of several non-randomized
trials would tend to overestimate the efficacy effect [52,53], or give
similar results [54,55], compared with randomized trials. Our
inclusion of these non-randomized trials might have favored a
valganciclovir beneficial effect, but in fact, the results still showed
no such superiority.
The high rate of tissue-invasive CMV disease observed in the
liver recipients of the pivotal trial [7] remains an important safety
concern. The statistically significant treatment by allograft
interaction both at 6 and at 12 months analyses suggest that
valganciclovir may be harmful to liver recipients. Similar high
rates of tissue-invasive CMV disease have also been observed in a
large retrospective study [38] of liver transplant recipients done
thereafter. Nonetheless, 61% [6] of liver transplant programs now
use valganciclovir prophylaxis despite the potentially negative
effects (tissue-invasive CMV disease) of this drug in this patient
population.
Singh et al [56] have argued that complete suppression of CMV
replication as a consequence of universal valganciclovir prophy-
laxis will likely not permit the host immune system to be exposed
to naturally occurring low-level episodes of CMV antigenemia.
Accordingly, the host remains ‘‘naı ¨ve’’ to CMV antigens until
valganciclovir prophylaxis ceases, at which time CMV reactivation
may occur without benefit of primed host responses. These so-
called ‘‘late-onset CMV infections’’ would therefore be expected to
occur more often with an anti-CMV agent that strongly suppress
replication, such as valganciclovir, as compared with acyclovir or
ganciclovir. In fact, we observed an 800% significant higher risk of
late-onset CMV disease with valganciclovir compared to acyclovir
prophylaxis or preemptive therapy, both of which may allow for
some intermittent replication of CMV and therefore, host
immunologic exposure. Our results indicate that one more patient
will develop late-onset CMV disease for every 25 recipients who
receive valganciclovir for CMV prophylaxis. Considering that late-
onset CMV disease is by itself a significant risk factor for death in
transplant recipients [57], this complication has important clinical
consequences.
Low-dose valganciclovir (450 mg daily) is an attractive potential
alternative to the currently recommended dose of 900 mg daily,
because it would presumably be associated with less toxicity, and
could allow for some low-level CMV replication that might be
immunologically advantageous. In fact, our analysis did not show
a significantly higher rate of neutropenia with valganciclovir
450 mg daily compared with ganciclovir, but the findings
suggested a 200% increase in the risk of neutropenia. Since the
sample sizes were limited, all controls used ganciclovir (which also
causes neutropenia), and all low-dose studies were retrospective,
the estimated risk of neutropenia associated with the 450 mg
valganciclovir dose may be understated here. While a prospective
study evaluating the efficacy and safety of the 450 mg dose
valganciclovir could add important information, the current data
does not suggest that this dose would cause less neutropenia than
the 900 mg dose.
A pre-emptive approach to prevention of CMV disease in the
SOT patient is also effective, and may lead to less drug exposure
than universal prophylaxis. However, once a positive CMV test
develops and triggers antiviral treatment, the typical duration of
therapy and maintenance is approximately 4–24 weeks [6], which
is of a similar duration to universal prophylaxis. Therefore, one
would expect that the side-effect profile of valganciclovir during
CMV Prevention
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universal prophylaxis. The reported rate of leucopenia (12–82%)
in observational trials with pre-emptive approach [17–24] is
similar or higher than the rates seen with valganciclovir universal
prophylaxis. On the other hand, ganciclovir is associated with
significantly lower risk of neutropenia in our study, and has
consistently demonstrated high efficacy when used preemptively
[2–4]. Compared to valganciclovir and IV ganciclovir, oral
ganciclovir has also demonstrated efficacy for preemptive
prevention of CMV disease [18,58]. Therefore, based on available
safety and efficacy data, oral ganciclovir should be considered the
most reasonable choice for the pre-emptive approach following
SOT.
Approximately 25,000 solid-organ transplants are performed
every year in the US, and according to a recent survey,
valganciclovir prophylaxis is being given to 62% of D+/R2,
53% of D+/R+, 48% of D2/R+, and 11% of D2/R2 patients
[5]. Thus, we estimate that 12,000 to 13,000 recipients are
prescribed valganciclovir prophylaxis every year. Based on the
approximately 8% neutropenia rate observed in the pivotal trial
[7] and in our study, 1,000 patients would develop significant
neutropenia related to valganciclovir each year. These numbers
are likely an underestimation because currently, many more
patients are taking valganciclovir prophylaxis for off-label
indications: T-cell depleting induction therapies; allograft rejec-
tions; prophylaxis for D+/R+,D 2/R+, and D2/R2 recipients;
CMV viremia without symptoms; and preemptive therapy. In fact,
the most recent survey showed that 61% of the transplant centers
are using valganciclovir for CMV prophylaxis in liver recipients
[6], despite the absence of an FDA indication. Given the adverse
effect profile noted in our analysis, the lack of superiority of the
drug against other standard therapies, and the increase in CMV
tissue-invasive disease, valganciclovir prophylaxis should be
contraindicated for all liver recipients until further data documents
its safety in this patient population. In fact, valganciclovir has not
been the prophylaxis regimen of choice for the high-risk liver
transplant recipients in our center since September 2003.
In conclusion, based on its significantly higher risk of
neutropenia, late-onset CMV disease, and its lack of superiority
against other standard therapies, valganciclovir is not the preferred
option as a first-line agent for CMV preemptive or universal
prophylaxis in SOT recipients, especially given the availability of
other efficacious, safer, and lower cost oral alternatives (e.g. high-
dose acyclovir, valacyclovir, ganciclovir).
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